The funding was led by SOSV and Graphene Ventures. Credit: CNW Group/Fluid AI Medical.

Canada-based FluidAI Medical has secured $15m in a Series A investment round to support its AI-powered postoperative patient monitoring system.

The round was led by SOSV and Graphene Ventures. Other investors including Boutique Venture Partners, Threshold Impact, Cur8 Capital, Leva Capital, Kyto Technology & Life Science, and Juno Pharmaceuticals also joined the fundraise.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Using the fresh infusion, FluidAI looks to enhance medical record integration, expand globally, and increase its staff headcount.

The company will also use the capital to develop artificial intelligence (AI)-based solutions for a wider range of postoperative complications.

FluidAI CEO Youssef Helwa said: “This funding not only validates our vision but also fuels our mission.

See Also:

“At FluidAI, our goal is to continuously push the boundaries of what’s possible in postoperative care, ensuring patients recover safely and quickly.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“With the trust and support of our investors, we’re poised to make a monumental impact on how data informs care decisions.”

FluidAI Medical specialises in using AI to monitor patients after surgery, helping to identify complications and adverse outcomes early.

The company stated that the surgical procedures can lead to complications. These include infections, bleeding, and wound healing issues, and in some cases, serious conditions such as anastomotic leaks, which can result in sepsis and death.

The complications are said to create additional burdens on healthcare systems, prolong hospital stays, and increase medical expenses.

To fix these, FluidAI’s Stream Platform uses advanced sensors and AI algorithms to detect anastomotic leaks, allowing for early intervention and improved clinical outcomes.

According to the company, this investment highlights the demand for solutions that enhance patient safety, reduce hospital stays, and lower healthcare costs.

SOSV GP Duncan Turner said: “FluidAI is a perfect example of AI-powered proprietary sensing being developed to save lives.

“With FluidAI, surgeons can ensure better clinical outcomes, shorter hospital stays for patients, and cost efficiencies across the healthcare ecosystem.

“We’re thrilled to back the FluidAI team, a passionate group of scientists, engineers and healthcare professionals who are leading this compelling development in post-operative care.”